References
- Ahmed H, Turner S. Severe asthma in children – a review of definitions, epidemiology, and treatment options in 2019. Pediatr Pulmonol. 2019 Jun;54(6):778–787.
- Severe asthma global initiative for asthma global strategy for asthma management and prevention. 2021. Available at: https://ginasthma.org/wp-content/uploads/2021/05/GINA-Main-Report-2021-V2-WMS.pdf. Accessed Apr 2022.
- Licari A, Manti S, Castagnoli R, et al. Immunomodulation in pediatric asthma. Front Pediatr. 2019 Jul 12;7:289
- Nucala (mepolizumab) prescribing information. 2022. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761122s008,125526s019lbl.pdf. Accessed Apr 2022.
- Sacha G, Rogers JA, Miller RL. Pre-filled syringes: a review of the history, manufacturing and challenges. Pharm Dev Technol. 2015;20(1):1–11.
- Fasenra (benralizumab) prescribing information. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761070s005lbl.pdf. Accessed Apr 2022.
- Dupixent (dupilumab) prescribing information. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761055s021s027s033lbl.pdf. Accessed Apr 2022.
- Xolair (omalizumab) prescribing information. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103976s5239lbl.pdf. Accessed Apr 2022.
- Tezspire (tezepelumab-ekko) prescribing information. 2021. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761224s000lbl.pdf. Accessed Apr 2022.
- Cinqair (reslizumab) prescribing information. 2019. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/0761033s010lbl.pdf. Accessed Apr 2022.
- Guarnieri G, Caminati M, Achille A, et al. Severe asthma, telemedicine, and self-administered therapy: listening first to the patient. J Clin Med. 2022 Feb 12;11(4):960.
- Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines – recommendations on the use of biologicals in severe asthma. Allergy. 2020 May;75(5):1023–1042.
- Gupta A, Pouliquen I, and Austin D, et al. Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma. Pediatr Pulmonol. 2019 Dec; 54(12):1957–1967. .
- Gupta A, Ikeda M, and Geng B, et al. Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype. J Allergy Clin Immunol. 2019 Nov; 144(5):1336–1342.e7. .
- Bel EH, I Bernstein D, and Bjermer L, et al. Usability of mepolizumab single-use prefilled syringe for patient self-administration. Epub 2019 Apr 24. PMID: 31017022, J Asthma. 2020 Jul;57(7):755–764. .
- Shabbir S, Pouliquen IJ, and Bentley JH, et al. The pharmacokinetics and relative bioavailability of mepolizumab 100 mg liquid formulation administered subcutaneously to healthy participants: a randomized trial. Clin Pharmacol Drug Dev. 2020 Apr; 9(3):375–385. .
- Cohen YZ, Zhang X, Xia B, et al. Pharmacokinetics of subcutaneous dupilumab injection with an autoinjector device or prefilled syringe. Clin Pharmacol Drug Dev. 2022 Mar 12;11(5):675–681.
- Pavord ID, Korn S, Howarth P, et al. Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet. 2012 Aug 18;380(9842):651–659.
- Ortega HG, Liu MC, Pavord ID, et al. MENSA investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1198–1207.
- Bel EH, Wenzel SE, Thompson PJ, et al. SIRIUS investigators. Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma. N Engl J Med. 2014 Sep 25;371(13):1189–1197.
- Chupp GL, Bradford ES, Albers FC, et al. Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial. Lancet Respir Med. 2017 May;5(5):390–400.
- Pouliquen IJ, Kornmann O, Barton SV, et al. Characterization of the relationship between dose and blood eosinophil response following subcutaneous administration of mepolizumab. Int J Clin Pharmacol Ther. 2015 Dec;53(12):1015–1027.
- Ortega HG, Yancey SW, Mayer B, et al. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies. Lancet Respir Med. 2016 Jul;4(7):549–556.
- Magnan A, Bourdin A, Prazma CM, et al. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy. 2016 Sep;71(9):1335–1344.
- Yancey SW, Ortega HG, Keene ON, et al. Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma. Allergy Asthma Clin Immunol. 2019 Sep 3;15(1):53.
- Khatri S, Moore W, Gibson PG, et al. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma. J Allergy Clin Immunol. 2019 May;143(5):1742–1751.e7.
- Khurana S, Brusselle GG, Bel EH, et al. Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study. Clin Ther. 2019 Oct;41(10):2041–2056.e5.
- Bernstein D, Pavord ID, Chapman KR, et al. Usability of mepolizumab single-use prefilled autoinjector for patient self-administration. J Asthma. 2020 Sep;57(9):987–998.
- Harrison T, Canonica GW, Chupp G, et al. Real-world mepolizumab in the prospective severe asthma REALITI-A study: initial analysis. Eur Respir J. 2020 Oct 15;56(4):2000151.
- Jackson D, Bacharier L, Gergen P, et al. Phenotype-directed therapy with mepolizumab for urban children with exacerbation-prone asthma. JACI. 2022 Feb;149(2):AB146.
- Noone J, Blanchette CM. The value of self-medication: summary of existing evidence. J Med Econ. 2018;21(2):201–211.
- Shaker M, Briggs A, Dbouk A, et al. Estimation of health and economic benefits of clinic versus home administration of omalizumab and mepolizumab. J Allergy Clin Immunol Pract. 2020 Feb;8(2):565–572.
- Evitt L, Follows R, and Williams W, et al. Mepolizumab self-administration via autoinjector and prefilled syringe: the qualitative patient experience. Eur Respir J. 2019;54(Suppl. 63):PA2518. DOI:10.1183/13993003.congress-2019.PA2518
- Rho YH, Rychlewska-Hańczewska A, Śliwowska B, et al. Usability of prefilled syringe and autoinjector for SB4 (an etanercept biosimilar) in patients with rheumatoid arthritis. Adv Ther. 2019 Sep;36(9):2287–2295.
- Stauffer VL, Sides R, Lanteri-Minet M, et al. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Prefer Adherence. 2018 Sep 17;12:1785–1795
- Roszkiewicz J, Swacha Z, Smolewska E. Prefilled pen versus prefilled syringe: a pilot study evaluating two different methods of methotrexate subcutaneous injection in patients with JIA. Pediatr Rheumatol Online J. 2020 Aug 12;18(1):64.
- Vermeire S, D’heygere F, Nakad A, et al. Preference for a prefilled syringe or an auto-injection device for delivering golimumab in patients with moderate-to-severe ulcerative colitis: a randomized crossover study. Patient Prefer Adherence. 2018 Jul 6;12:1193–1202